RxDoctor Payments DataLook up a doctor →

Michael Cunningham, MD

Interventional Cardiology · Biloxi, MSNPI 1821219106

Payments from drug & device makers

$44,670in general payments, 2019–2025

Across 805 payments — averaging $55.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Edwards Lifesciences$5K
  • Boston Scientific$3K
  • Abbott$1K
  • Silk Road Medical, Inc.$1K
  • Abiomed$1K
  • plus $10K from 44 others

What the payments were for

  • Speaking & faculty fees$2,9257%
  • Travel & lodging$22,17550%
  • Food & beverage$18,58742%
  • Education$840%
  • Gifts$750%
  • Other$8242%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,670 in reported general payments places this provider in the 75th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$452,641
Medicare patients
1,060
Services billed
4,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$419,533
EntrestoSacubitril/Valsartan167$182,050
XareltoRivaroxaban124$117,112
BrilintaTicagrelor72$49,395
Repatha SureclickEvolocumab48$42,742
FarxigaDapagliflozin Propanediol34$33,831
JardianceEmpagliflozin27$21,146
NexlizetBempedoic Acid/Ezetimibe24$16,324
Ranolazine ErRanolazine61$4,174
Metoprolol Succinate272$3,005
ClopidogrelClopidogrel Bisulfate328$2,780
Amiodarone Hcl179$2,754
Atorvastatin Calcium355$2,670
Valsartan81$2,336
Rosuvastatin Calcium178$2,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$569$419,533437 claims
NovartisEntresto$936$182,050167 claims
Johnson & JohnsonXarelto$712$117,112124 claims
AstraZenecaBrilinta, Farxiga$144$83,226106 claims
Boehringer IngelheimJardiance$147$21,14627 claims
Esperion Therapeutics, Inc.Nexlizet$249$16,32424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →